AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25857939 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening treatment with a prefabricated orthosis, stretching, and strengthening exercises
Number of subjects: 39
Study 25857939 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthosis wear alone)
Number of subjects: 39
Study 23187047 — intervention group
Group type: EXPERIMENTAL
Intervention: Delorme operation only (GI)
Number of subjects: 82
Study 23187047 — intervention group
Group type: EXPERIMENTAL
Intervention: Delorme operation with postanal repair and levatorplasty (GII)
Number of subjects: 82
Study 20419494 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 320 mg PO
Number of subjects: 100
Study 20419494 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg IV + Metoclopramide 20 mg IM (no megestrol acetate)
Number of subjects: 100
Study 20419494 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate regimen
Number of subjects: 100
Study 20419494 — intervention group
Group type: COMPARATOR
Intervention: No megestrol acetate regimen
Number of subjects: 100
Study 19384234 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-integrated central venous catheters
Number of subjects: 230
Study 19384234 — intervention group
Group type: COMPARATOR
Intervention: Standard central venous catheters
Number of subjects: 230
Study 17303485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova T380
Number of subjects: 957
Study 17303485 — intervention group
Group type: COMPARATOR
Intervention: Gyne T380 Slimline
Number of subjects: 957
Study 17303485 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 957
Study 15179542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood and Physical Symptoms Scale (MPSS)
Number of subjects: 111
Study 15179542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of urges to smoke
Number of subjects: 111
Study 15179542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of hunger
Number of subjects: 111
Study 11702960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 1000
Study 11702960 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation
Number of subjects: 1000
Study 11702960 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation (70 Gy in 7 weeks)
Number of subjects: 1000
Study 1606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg and 100 mg)
Number of subjects: 10
Study 1606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg and 100 mg)
Number of subjects: 10
Study 1606999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4075074 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic treatment (4 sessions over one week)
Number of subjects: 12
Study 4075074 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic treatment (8 sessions over two weeks)
Number of subjects: 12
Study 4075074 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological treatment (4 sessions over one week)
Number of subjects: 12
Study 4075074 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological treatment (8 sessions over two weeks)
Number of subjects: 12
Study 29582641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening
Number of subjects: 320
Study 29582641 — intervention group
Group type: COMPARATOR
Intervention: Marital status
Number of subjects: 320
Study 29582641 — intervention group
Group type: COMPARATOR
Intervention: Knowledge
Number of subjects: 320
Study 29582641 — intervention group
Group type: COMPARATOR
Intervention: Perceived barriers
Number of subjects: 320
Study 29582641 — intervention group
Group type: COMPARATOR
Intervention: Having a regular health care provider
Number of subjects: 320
Study 27286139 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (15 mg/day for patients ≥30 kg and 25 mg/day for patients ≥45 kg)
Number of subjects: 54
Study 27286139 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) (20 mg/day for participants <30 kg and 30 mg/day for patients ≥30 kg)
Number of subjects: 54
Study 27286139 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 54
Study 24785925 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention (transpalatal arch)
Number of subjects: 30
Study 24785925 — intervention group
Group type: COMPARATOR
Intervention: No retention
Number of subjects: 30
Study 23536452 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctic Ease cryotherapy wrap
Number of subjects: 13
Study 23536452 — intervention group
Group type: COMPARATOR
Intervention: Traditional ice pack and compression wrap (control group)
Number of subjects: 13
Study 20685951 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain foods (3 daily portions)
Number of subjects: 206
Study 20685951 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain foods (wheat + oats)
Number of subjects: 206
Study 20685951 — intervention group
Group type: COMPARATOR
Intervention: Refined diet (control)
Number of subjects: 206
Study 19066755 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 16860894 — intervention group
Group type: EXPERIMENTAL
Intervention: BAD (bootstrapped amplitude difference) method
Number of subjects: 0
Study 16860894 — intervention group
Group type: EXPERIMENTAL
Intervention: BCD (bootstrapped correlation difference) method
Number of subjects: 0
Study 16860894 — intervention group
Group type: EXPERIMENTAL
Intervention: New approach with wavelet features and a statistical classifier
Number of subjects: 0
Study 12564610 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg sibenadet via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Number of subjects: 435
Study 12564610 — intervention group
Group type: COMPARATOR
Intervention: Placebo via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Number of subjects: 435
Study 10627444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines (240 mg/m²) and cyclophosphamide (3 g/m²) with prophylactic cranial irradiation (12 Gy)
Number of subjects: 105
Study 10627444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for patients with less than 70% tumor regression on day 33
Number of subjects: 105
Study 10627444 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tumor residues after induction
Number of subjects: 105
Study 10627444 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete tumor regression
Number of subjects: 105
Study 10627444 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall events
Number of subjects: 105
Study 8972656 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical CT
Number of subjects: 33
Study 8972656 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 33
Study 1735396 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 37.5 mg or 75 mg
Number of subjects: 0
Study 1735396 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 25 mg or 50 mg
Number of subjects: 0
Study 1735396 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 5 mg or 10 mg
Number of subjects: 0
Study 1735396 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 3544689 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg tid
Number of subjects: 12
Study 3544689 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg bid
Number of subjects: 12
Study 3544689 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose regimen
Number of subjects: 12
Study 3544689 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose regimen
Number of subjects: 12
Study 3544689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2-dose and 3-dose regimens
Number of subjects: 12
Study 29718556 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training and dietary advice (F+D)
Number of subjects: 50
Study 29718556 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (D)
Number of subjects: 50
Study 27394191 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 200
Study 27394191 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 200
Study 24456823 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus 25mg weekly
Number of subjects: 71
Study 24456823 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus with megestrol acetate 80 mg bid for three weeks alternating with tamoxifen 20mg bid for three weeks
Number of subjects: 71
Study 23250594 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (MENS) in addition to standard treatment (n=36)
Number of subjects: 105
Study 23250594 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (MENS) in combination with cortexin (n=38)
Number of subjects: 105
Study 23250594 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy using massage and gymnastics (n=31)
Number of subjects: 105
Study 22216654 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% sodium fluoride, specially-designed silica)
Number of subjects: 115
Study 22216654 — intervention group
Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 115
Study 19268053 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen avoidance for 1 month (T1)
Number of subjects: 22
Study 19268053 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen avoidance for 4 months (T2)
Number of subjects: 22
Study 19268053 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen avoidance regimen
Number of subjects: 22
Study 17044273 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated stents
Number of subjects: 60
Study 17044273 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 60
Study 12769249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 894
Study 12769249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 894
Study 11141203 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial standard rate intervention (80-90 beats/min)
Number of subjects: 20
Study 11141203 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial high rate intervention (120 beats/min)
Number of subjects: 20
Study 11141203 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rate)
Number of subjects: 20
Study 9180672 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS (7.5 mg)
Number of subjects: 78
Study 9180672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 1610024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemirolast 50 mg BID
Number of subjects: 96
Study 1610024 — intervention group
Group type: COMPARATOR
Intervention: Pemirolast 25 mg BID
Number of subjects: 96
Study 1610024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 3864227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (less than 25 en% total fat, high P/S ratio diet 0.4-1.1)
Number of subjects: 3
Study 3864227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (less than 25 en% total fat, P/S ratio 0.9) with 60% salt reduction
Number of subjects: 3
Study 3864227 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (less than 25 en% total fat, P/S ratio 0.4 and 0.9)
Number of subjects: 3
Study 30456961 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiga toxin-producing Escherichia coli (STEC) isolates
Number of subjects: 540
Study 30456961 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial susceptibility testing
Number of subjects: 540
Study 30456961 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of class 1 integrons
Number of subjects: 540
Study 26739977 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Number of subjects: 57
Study 26739977 — intervention group
Group type: COMPARATOR
Intervention: Non-elastic abdominal binder
Number of subjects: 57
Study 24642702 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (MMI)
Number of subjects: 278
Study 24642702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-based-behavioral therapy (CBT)
Number of subjects: 278
Study 24642702 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 278
Study 22345500 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase delivered through a microcatheter embedded within the thrombus at 1 mg per minute, not exceeding 100 mg total
Number of subjects: 85
Study 22345500 — intervention group
Group type: COMPARATOR
Intervention: Standard alteplase delivery method without optimization
Number of subjects: 85
Study 22345500 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimizing alteplase delivery
Number of subjects: 85
Study 19895624 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cognitive behaviourally oriented service (CBOS)
Number of subjects: 169
Study 19895624 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 169
Study 17986242 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (20 mug type 6, 40 mug type 11, 40 mug type 16, and 20 mug type 18)
Number of subjects: 176
Study 17986242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 16095844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 88
Study 16095844 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education (PET)
Number of subjects: 88
Study 11849196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 1.0 mg twice daily for 23 days and once on day 24 (continuous dosing)
Number of subjects: 3
Study 11849196 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 1.0 mg single dose on days 1, 5, 10, 17, and 24 (intermittent dosing)
Number of subjects: 3
Study 11849196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo capsules under the same regimen as group 1)
Number of subjects: 3
Study 10399790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodular RA
Number of subjects: 105
Study 10399790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nodular RA
Number of subjects: 105
Study 10399790 — intervention group
Group type: COMPARATOR
Intervention: Control group (Osteoarthrosis and Spondyloarthrosis)
Number of subjects: 105
Study 7741287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms.kg‐1
Number of subjects: 96
Study 7741287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms.kg‐1
Number of subjects: 96
Study 7741287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 7741287 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 96
Study 2126672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap (CP-66,248)
Number of subjects: 10
Study 7234399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological examination of cerebrospinal fluid with histiomonocytic counts greater than 10 M. elements/l and granulocytic peaks greater than 2 M. elements/l
Number of subjects: 57
Study 31837726 — intervention group
Group type: EXPERIMENTAL
Intervention: Varied Practice (n=405)
Number of subjects: 827
Study 31837726 — intervention group
Group type: COMPARATOR
Intervention: Repeated Reading (n=422)
Number of subjects: 827
Study 28379486 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic modeling with postdialysis serum creatinine measurement
Number of subjects: 366
Study 28379486 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic modeling without postdialysis serum creatinine measurement
Number of subjects: 366
Study 28379486 — intervention group
Group type: COMPARATOR
Intervention: Diffusive cross-dialyzer clearances of urea
Number of subjects: 366
Study 26485128 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact intervention (testimonies, participatory videos, and comics during contact events)
Number of subjects: 4443
Study 23408577 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) therapy for 5 years followed by a 5-year treatment-free period (placebo arm of the FLEX trial)
Number of subjects: 406
Study 21555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists providing information regarding medication's name (93.3%)
Number of subjects: 540
Study 21555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists providing dosage schedule (92.8%)
Number of subjects: 540
Study 21555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists advising daily medication intake (92.6%)
Number of subjects: 540
Study 21555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists informing about time to effect (87.8%)
Number of subjects: 540
Study 21555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists providing less information to Spanish-speaking patients (β = ‐0.24)
Number of subjects: 540
Study 21555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists providing less education messages to Spanish-speaking patients (β = ‐0.17)
Number of subjects: 540
Study 19379703 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis-PAGE protocol for bisulfite conversion
Number of subjects: 200
Study 19379703 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary-based size analysis and Sanger sequencing
Number of subjects: 200
Study 17038641 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs
Number of subjects: 26
Study 15243743 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 280
Study 15243743 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 280
Study 15243743 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP repair
Number of subjects: 280
Study 11078635 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol (20 ml)
Number of subjects: 20
Study 11078635 — intervention group
Group type: COMPARATOR
Intervention: normal saline solution (20 ml)
Number of subjects: 20
Study 9093234 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive therapy for disseminated or invasive fungal infections; details on dosage and duration not available.
Number of subjects: 0
Study 8287659 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg orally)
Number of subjects: 6
Study 8287659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2892963 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Timolol
Number of subjects: 15
Study 2892963 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% Metipranolol
Number of subjects: 15
Study 2892963 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 15
Study 2892963 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Pindolol
Number of subjects: 15
Study 2892963 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Pilocarpin
Number of subjects: 15
Study 29556144 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system derived from backward stepwise logistic regression model
Number of subjects: 976
Study 29556144 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system with total score >9.5
Number of subjects: 976
Study 29556144 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of CSX
Number of subjects: 976
Study 27737480 — intervention group
Group type: EXPERIMENTAL
Intervention: Home management
Number of subjects: 239
Study 27737480 — intervention group
Group type: COMPARATOR
Intervention: Hospital management
Number of subjects: 239
Study 24998039 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-layered spineboard
Number of subjects: 30
Study 24998039 — intervention group
Group type: COMPARATOR
Intervention: Rigid spineboard
Number of subjects: 30
Study 23218961 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential suction electrode (DSE) probe
Number of subjects: 20
Study 23218961 — intervention group
Group type: COMPARATOR
Intervention: Femiscan™ probe
Number of subjects: 20
Study 23218961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both probes
Number of subjects: 20
Study 20216532 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-gauge needle
Number of subjects: 117
Study 20216532 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge needle
Number of subjects: 117
Study 18398080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment (LDL-C target of 70 mg/dL or lower, SBP target of 115 mm Hg or lower)
Number of subjects: 499
Study 18398080 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (LDL-C target of 100 mg/dL or lower, SBP target of 130 mm Hg or lower)
Number of subjects: 499
Study 18398080 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive treatment
Number of subjects: 499
Study 18398080 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 499
Study 15343465 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-tube thoracostomy
Number of subjects: 30
Study 15343465 — intervention group
Group type: COMPARATOR
Intervention: Open thoracotomy
Number of subjects: 30
Study 11395836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea‐Bands with acupressure on both wrists
Number of subjects: 157
Study 11395836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea‐Bands with acupressure on one wrist
Number of subjects: 157
Study 11395836 — intervention group
Group type: COMPARATOR
Intervention: Wristband without acupressure on both wrists
Number of subjects: 157
Study 11395836 — intervention group
Group type: COMPARATOR
Intervention: Wristband without acupressure on one wrist
Number of subjects: 157
Study 11395836 — intervention group
Group type: COMPARATOR
Intervention: No wristband
Number of subjects: 157
Study 9664269 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (MLD) for 45 min/day for 2 weeks
Number of subjects: 28
Study 9664269 — intervention group
Group type: COMPARATOR
Intervention: Sequential pneumatic compression (SPC) with a pressure of 40‐60 mmHg for 2 hours/day for 2 weeks
Number of subjects: 28
Study 2905064 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension therapy (abrupt discontinuation of neuroleptics)
Number of subjects: 159
Study 30508408 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2.0 mA, 20 minutes, five days)
Number of subjects: 11
Study 30508408 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 11